

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application. All amendments and cancellations are made without prejudice.


Listing of Claims

1. (Allowed) A method of inhibiting the maturation of an antigen presenting that is a dendritic cell, comprising contacting *in vitro* said antigen presenting cell and an effective amount of the synthetic polymeric antigen or pharmaceutically acceptable salt thereof of claim 31, for a time and under conditions effective to inhibit maturation of said antigen presenting cell.
2. (cancelled)
3. (Allowed) The method of claim 1, wherein inhibition of maturation of said antigen presenting cell is accompanied by a reduction in the level of expression of one or more surface markers selected from the group consisting of CD80 and CD86 by said antigen presenting cell.
4. (Allowed) The method of claim 1, wherein inhibition of maturation of said antigen presenting cell is accompanied by a reduction in the level of expression of one or more cytokines selected from the group consisting of IL6, IL12, interferon alpha, and interferon gamma by said antigen presenting cell.
5. (cancelled)
6. (cancelled)
7. (cancelled)
8. (cancelled)

9. (Allowed) A method of increasing the expression of interleukin 10 (IL10) in a mammal in need thereof, comprising:
- (a) isolating peripheral blood mononuclear cells, or a monocyte-containing fraction thereof, from said mammal;
 - (b) contacting *in vitro* said isolated peripheral blood mononuclear cells or monocytes and a composition containing an effective amount of cytokines that differentiate monocytes to immature dendritic cells for a time and under conditions effective to generate immature monocyte-derived dendritic cells;
 - (c) contacting *in vitro* said immature monocyte-derived dendritic cells and an effective amount of the synthetic polymeric antigen or pharmaceutically acceptable salt thereof of claim 31, for a time and under conditions effective to prevent maturation of said immature monocyte-derived dendritic cells; and
 - (d) administering said immature monocyte-derived dendritic cells to said mammal, thereby increasing the expression of IL10 in said mammal.
10. (Allowed) The method of claim 9, wherein said cytokine composition of step (b) comprises granulocyte-macrophage colony-stimulating factor and IL4.
11. (cancelled)
12. (cancelled)
13. (cancelled)
14. (cancelled)
15. (cancelled)

16. (original) The method of claim 15, further comprising contacting said T regulatory cells and IL2 for a time and under conditions effective to expand the number of said T regulatory cells.
17. (cancelled)
18. (cancelled)
19. (cancelled)
20. (cancelled)
21. (cancelled)
22. (cancelled)
23. (cancelled)
24. (cancelled)
25. (cancelled)
26. (cancelled)
27. (cancelled)
28. (cancelled)
29. (cancelled)
30. (cancelled)

31. (Allowed) A synthetic polymeric antigen having the structure shown in Formula I:



where n is an integral in the range of from about 375 to about 75,
or a pharmaceutically acceptable salt thereof.

32. (Allowed) A composition, comprising said synthetic polymeric antigen or pharmaceutically acceptable salt thereof of claim 31, and a buffer, carrier, diluent, or excipient.
33. (Allowed) A pharmaceutical composition, comprising said synthetic polymeric antigen or pharmaceutically acceptable salt thereof of claim 31, and a pharmaceutically acceptable buffer, carrier, diluent, or excipient.
34. (cancelled)
35. (cancelled)

- 36. (cancelled)
- 37. (cancelled)
- 38. (cancelled)
- 39. (cancelled)
- 40. (cancelled)
- 41. (Allowed) A solution comprising said synthetic polymeric antigen or pharmaceutically acceptable salt thereof of claim 31, and a solvent.
- 42. (cancelled)
- 43. (cancelled)
- 44. (cancelled)